Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

por Raaijmakers, Marieke I. G., Widmer, Daniel S., Narechania, Apurva, Eichhoff, Ossia, Freiberger, Sandra N., Wenzina, Judith, Cheng, Phil F., Mihic-Probst, Daniela, Desalle, Rob, Dummer, Reinhard, Levesque, Mitchell P.
Publicado 2016